Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars

Set Alert for Biosimilars

Canadian Originators Are Free To Try Again

Having unsuccessfully asserted a patent under the previous legal framework in Canada does not preclude an originator from trying again following legislative amendments enacted in 2017, the country’s Federal Court of Appeal has ruled in a decision on Pfizer’s Nivestym filgrastim biosimilar.

Canada Intellectual Property

Dutch Watchdog Questions Conditional Rebates For Biologics

Originators that make discounts on biologic list prices conditional on hospitals not switching treatment to anti-TNF biosimilars may be breaching competition law, the Netherlands’ competition authority is warning.

Biosimilars Netherlands

Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Biosimilars Strategy

Nine Factors Can Drive Hospital-Sector Savings

A KPMG report commissioned by Medicines for Europe finds that nine ‘key ingredients’ could maximize savings for generic and biosimilar medicines in European hospitals.

Government Payers Europe

US Biosimilar Fee Collections Fall Short

A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.

Regulation Biosimilars

Belgium Launches Probe On Biosimilar Restrictions

Belgium’s competition regulator has announced that it is investigating practices that have restricted or prevented biosimilars from entering the market.

Biosimilars Belgium
See All
UsernamePublicRestriction

Register

Advertisement